The specialized $41.2 million facility will support production of viral vectors for cell and gene therapies to treat certain cancers and autoimmune and genetic diseases.
President Trump’s proposed tariffs on Canada, China, and Mexico may delay new investments until policies become clearer, according to data analytics firm GlobalData.
CEO David Ricks in a Thursday earnings call touted the $23 billion that Lilly has spent on expanding its manufacturing capabilities to meet growing GLP-1 demand.
This year’s investment is an increase from the nearly $6.3 billion the Danish drugmaker spent in 2024 to bolster its manufacturing capabilities and similar projects.
The company said the system, installed in Wasserburg, Germany, performs aseptic filling within a Grade A isolator and operates in full compliance with GMP standards.
The company planned to expand an existing facility in Speke, Liverpool, but said the UK government made a final funding offer that was lower than previously proposed.
The CDMO will manufacture clinical batches of JOTROL, Jupiter’s resveratrol-based therapeutic, to support its Phase 2a clinical trial in Parkinson’s disease.
The CDMO’s new facility was designed to align with the updated EU GMP Annex-1 regulations and features two cleanrooms with advanced VHP isolation technology.
The South Korean manufacturer and exporter of biosimilars said it is prepared to respond regardless of how the Trump administration’s drug tariff policy might be implemented.
CDMO sales helped compensate for lower market demand for pharma capsules and softness in the company’s bioscience business, Lonza reported on Wednesday.
Evergreen’s scalable manufacturing capabilities are meant to enhance Lantheus Holdings’ ability to meet the complex demands of radiopharmaceutical development and production.
India’s contract development and manufacturing organization market is expected to grow from $7 billion to $14 billion by 2028, capturing 4% to 5% of the global CDMO market.
On average, respondents said they expect a decline in services spending this year versus 2024, according to a survey commissioned by analyst firm Leerink Partners.
Backed by Delin Ventures, the company aims to transform cancer treatment by creating therapies achieving long-term remission for patients with advanced metastatic cancers.
The cell therapy CDMO will provide technology transfer, analytical method transfer, and cGMP manufacturing to support Secretome Therapeutics’ lead asset STM-01.
The integrated CDMO is aiming to enhance manufacturing efficiencies for KaloCyte’s lead candidate, ErythroMer, a bioengineered artificial red blood cell substitute.
The companies will jointly develop and supply a portfolio of novel central nervous system-focused products using Spektus Pharma’s proprietary Flexitab technology.
The clinical hold is linked to GMP compliance issues identified during an inspection of a third-party manufacturing facility that was the basis of a Complete Response Letter.
